Total body irradiation, cyclophosphamide, and etoposide with stem cell transplant as treatment for infants with acute lymphocytic leukemia

Laura Pirich*, Paul Haut, Elaine R Morgan, Maryann Marymount, Morris Kletzel

*Corresponding author for this work

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background. Acute lymphoblastic leukemia (ALL) in infants has a very poor outcome with modern chemotherapy. We reviewed our experience with the infants diagnosed with ALL at Children's Memorial Hospital from 1992 to 1997. Procedure. During this time period, 10 infants were diagnosed with ALL. Seven of them were transplanted, four with marrow from HLA-matched siblings and three with umbilical cord blood. Four of the transplanted patients had the MLL gene rearrangement and the other three transplanted patients had one or more other high-risk features including CD10-blasts, age less than 6 months at diagnosis, or prior relapse. The patients were conditioned with a regimen of total body irradiation (TBI), etoposide, and cyclophosphamide (CY). Peritransplant toxicity was tolerable. The graft infused contained a median total nucleated cell dose/kg of 3 x 108 (.3 x 108-6 x 108). The median CD34+ cell dose/kg was 5 x 106 (.25 x 106-31 x 106). Results. All of the patients engrafted with a median of 18 days (11-29) to reach an absolute neutrophil count (ANC) of 500/μl. The median time to reach an unsupported platelet count greater than 20,000/μl was 24 days (1864). Four of seven of the transplanted patients are leukemia-free survivors at a median follow-up of 775 days. Of the three patients who were not transplanted, one is surviving 2+ years off therapy. Conclusions. Allogeneic stem cell transplant is an alternative to chemotherapy alone as a treatment for infant ALL when a suitable donor is available.

Original languageEnglish (US)
Pages (from-to)1-6
Number of pages6
JournalMedical and Pediatric Oncology
Volume32
Issue number1
DOIs
StatePublished - Jan 1 1999

Fingerprint

Whole-Body Irradiation
Etoposide
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Cyclophosphamide
Stem Cells
Transplants
Therapeutics
Drug Therapy
Gene Rearrangement
Platelet Count
Fetal Blood
Survivors
Siblings
Leukemia
Neutrophils
Bone Marrow
Tissue Donors
Recurrence

Keywords

  • Bone marrow transplant
  • Infant leukemia
  • Total body irradiation

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Cancer Research

Cite this

@article{e997dbd22f5240a993835c1e4a978b5f,
title = "Total body irradiation, cyclophosphamide, and etoposide with stem cell transplant as treatment for infants with acute lymphocytic leukemia",
abstract = "Background. Acute lymphoblastic leukemia (ALL) in infants has a very poor outcome with modern chemotherapy. We reviewed our experience with the infants diagnosed with ALL at Children's Memorial Hospital from 1992 to 1997. Procedure. During this time period, 10 infants were diagnosed with ALL. Seven of them were transplanted, four with marrow from HLA-matched siblings and three with umbilical cord blood. Four of the transplanted patients had the MLL gene rearrangement and the other three transplanted patients had one or more other high-risk features including CD10-blasts, age less than 6 months at diagnosis, or prior relapse. The patients were conditioned with a regimen of total body irradiation (TBI), etoposide, and cyclophosphamide (CY). Peritransplant toxicity was tolerable. The graft infused contained a median total nucleated cell dose/kg of 3 x 108 (.3 x 108-6 x 108). The median CD34+ cell dose/kg was 5 x 106 (.25 x 106-31 x 106). Results. All of the patients engrafted with a median of 18 days (11-29) to reach an absolute neutrophil count (ANC) of 500/μl. The median time to reach an unsupported platelet count greater than 20,000/μl was 24 days (1864). Four of seven of the transplanted patients are leukemia-free survivors at a median follow-up of 775 days. Of the three patients who were not transplanted, one is surviving 2+ years off therapy. Conclusions. Allogeneic stem cell transplant is an alternative to chemotherapy alone as a treatment for infant ALL when a suitable donor is available.",
keywords = "Bone marrow transplant, Infant leukemia, Total body irradiation",
author = "Laura Pirich and Paul Haut and Morgan, {Elaine R} and Maryann Marymount and Morris Kletzel",
year = "1999",
month = "1",
day = "1",
doi = "10.1002/(SICI)1096-911X(199901)32:1<1::AID-MPO2>3.0.CO;2-J",
language = "English (US)",
volume = "32",
pages = "1--6",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "1",

}

Total body irradiation, cyclophosphamide, and etoposide with stem cell transplant as treatment for infants with acute lymphocytic leukemia. / Pirich, Laura; Haut, Paul; Morgan, Elaine R; Marymount, Maryann; Kletzel, Morris.

In: Medical and Pediatric Oncology, Vol. 32, No. 1, 01.01.1999, p. 1-6.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Total body irradiation, cyclophosphamide, and etoposide with stem cell transplant as treatment for infants with acute lymphocytic leukemia

AU - Pirich, Laura

AU - Haut, Paul

AU - Morgan, Elaine R

AU - Marymount, Maryann

AU - Kletzel, Morris

PY - 1999/1/1

Y1 - 1999/1/1

N2 - Background. Acute lymphoblastic leukemia (ALL) in infants has a very poor outcome with modern chemotherapy. We reviewed our experience with the infants diagnosed with ALL at Children's Memorial Hospital from 1992 to 1997. Procedure. During this time period, 10 infants were diagnosed with ALL. Seven of them were transplanted, four with marrow from HLA-matched siblings and three with umbilical cord blood. Four of the transplanted patients had the MLL gene rearrangement and the other three transplanted patients had one or more other high-risk features including CD10-blasts, age less than 6 months at diagnosis, or prior relapse. The patients were conditioned with a regimen of total body irradiation (TBI), etoposide, and cyclophosphamide (CY). Peritransplant toxicity was tolerable. The graft infused contained a median total nucleated cell dose/kg of 3 x 108 (.3 x 108-6 x 108). The median CD34+ cell dose/kg was 5 x 106 (.25 x 106-31 x 106). Results. All of the patients engrafted with a median of 18 days (11-29) to reach an absolute neutrophil count (ANC) of 500/μl. The median time to reach an unsupported platelet count greater than 20,000/μl was 24 days (1864). Four of seven of the transplanted patients are leukemia-free survivors at a median follow-up of 775 days. Of the three patients who were not transplanted, one is surviving 2+ years off therapy. Conclusions. Allogeneic stem cell transplant is an alternative to chemotherapy alone as a treatment for infant ALL when a suitable donor is available.

AB - Background. Acute lymphoblastic leukemia (ALL) in infants has a very poor outcome with modern chemotherapy. We reviewed our experience with the infants diagnosed with ALL at Children's Memorial Hospital from 1992 to 1997. Procedure. During this time period, 10 infants were diagnosed with ALL. Seven of them were transplanted, four with marrow from HLA-matched siblings and three with umbilical cord blood. Four of the transplanted patients had the MLL gene rearrangement and the other three transplanted patients had one or more other high-risk features including CD10-blasts, age less than 6 months at diagnosis, or prior relapse. The patients were conditioned with a regimen of total body irradiation (TBI), etoposide, and cyclophosphamide (CY). Peritransplant toxicity was tolerable. The graft infused contained a median total nucleated cell dose/kg of 3 x 108 (.3 x 108-6 x 108). The median CD34+ cell dose/kg was 5 x 106 (.25 x 106-31 x 106). Results. All of the patients engrafted with a median of 18 days (11-29) to reach an absolute neutrophil count (ANC) of 500/μl. The median time to reach an unsupported platelet count greater than 20,000/μl was 24 days (1864). Four of seven of the transplanted patients are leukemia-free survivors at a median follow-up of 775 days. Of the three patients who were not transplanted, one is surviving 2+ years off therapy. Conclusions. Allogeneic stem cell transplant is an alternative to chemotherapy alone as a treatment for infant ALL when a suitable donor is available.

KW - Bone marrow transplant

KW - Infant leukemia

KW - Total body irradiation

UR - http://www.scopus.com/inward/record.url?scp=0032931681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032931681&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1096-911X(199901)32:1<1::AID-MPO2>3.0.CO;2-J

DO - 10.1002/(SICI)1096-911X(199901)32:1<1::AID-MPO2>3.0.CO;2-J

M3 - Article

VL - 32

SP - 1

EP - 6

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 1

ER -